The current global healthcare landscape is increasingly threatened by the emergence of multidrug-resistant fungal strains. This phenomenon has prompted international health organizations to classify several fungal pathogens, including two species belonging to the genus Candida, among pathogens of critical priority. Current therapeutic strategies, which rely predominantly on azoles, polyenes, and echinocandins, are subject to significant limitations due to the emergence of resistance mechanisms and the toxicity associated with some treatments. An additional major challenge affecting healthcare systems is represented by skin wounds, particularly chronic wounds, which are associated with high morbidity and substantial economic costs, thereby contributing to delays in the clinical management of affected patients. The healing of these lesions is frequently impaired by the development of polymicrobial infections, in which Candida represents a clinically relevant pathogen. Within this context, phenylethanoid glycosides, owing to their antimicrobial and anti inflammatory properties, may represent potential multifunctional therapeutic agents, as they have the potential to target two critical aspects of wound management: infection control and the inflammatory processes involved in wound healing. The aim of the present thesis was to evaluate the antifungal activity of two plant-derived compounds, ABR1 and ABR2, containing the phenylethanoid glycosides verbascoside and plantamajoside, respectively, using C. albicans as the reference organism. Their antifungal activity was assessed both as single agents and in combination with amphotericin B. In addition, ABR2 was tested against 15 clinical isolates belonging to the genus Candida. A preliminary assessment of cytotoxicity was performed using 3T3 fibroblasts, and an in vitro skin wound model was established by means of a scratch assay. The results showed that ABR1 and ABR2 exhibited antifungal activity when administered as single agents at concentrations of 40,000 mg/L and 48,000 mg/L, respectively. In the presence of amphotericin B at 0.0625 mg/L, the effective concentrations decreased to 156 mg/L and 188 mg/L, respectively. The analysis of the clinical isolates revealed a variable response to ABR2. Finally, the experiments performed on fibroblasts and the scratch assay indicated that ABR1 and ABR2, at concentrations effective in combination with amphotericin B, were compatible with fibroblast viability when administered as single agents, whereas their combination with amphotericin B resulted in reduced cellular compatibility, likely due to limited selectivity.
Il panorama sanitario globale attuale è minacciato dall’emergenza di ceppi fungini multi resistenti; questo fenomeno ha spinto le organizzazioni sovranazionali a classificare alcuni funghi, tra cui due del genere Candida, entro gruppi di patogeni a priorità critica. Le attuali strategie terapeutiche, basate prevalentemente sull’utilizzo di azoli, polieni ed echinocandine, presentano importanti limiti dovuti alla comparsa di meccanismi di resistenza e alla tossicità associata ad alcuni trattamenti. Un ulteriore problema che affligge il sistema sanitario è rappresentato dalle ferite cutanee, in particolare quelle croniche, gravate da elevata morbilità e ingenti costi economici che rallentano i percorsi di cura. La guarigione di queste lesioni è frequentemente ostacolata dall’insorgenza di infezioni polimicrobiche, all’interno delle quali Candida è un patogeno cruciale. In questo contesto, i glicosidi feniletanoidi, grazie alle loro proprietà antimicrobiche e antinfiammatorie, si inseriscono come possibili agenti terapeutici multifunzionali grazie alla possibilità di agire su due fronti critici nel processo di guarigione delle ferite e di controllo delle infezioni. La presente tesi ha avuto come obiettivo la valutazione dell’attività antimicotica di due composti di origine vegetale, ABR1 ed ABR2, contenenti rispettivamente i glicosidi feniletanoidi verbascoside e plantamajoside, utilizzando C. albicans come organismo di riferimento. È stata valutata l’azione sia in uso singolo che in combinazione con amfotericina B. Inoltre, ABR2 è stato testato su 15 isolati clinici appartenenti al genere Candida. È stata valutata in maniera preliminare la citotossicità sui fibroblasti della linea 3T3 ed è stato impostato un modello in vitro di ferita cutanea mediante scratch assay. I risultati evidenziano che ABR1 e ABR2 manifestano attività antimicotica singolarmente a 40000 mg/L e 48000 mg/L. Le concentrazioni efficaci si riducono a 156 mg/L e 188 mg/L in presenza di amfotericina B 0,0625 mg/L. L’analisi sugli isolati clinici mette in evidenza una risposta variabile ad ABR2. Infine, dagli esperimenti eseguiti sui fibroblasti e dallo scratch assay, si osserva che ABR1 e ABR2 alle concentrazioni efficaci in sinergia risultano compatibili con la vitalità dei fibroblasti, mentre non lo sono in combinazione con amfotericina B a causa della scarsa selettività.
Attività antimicotica dei glicosidi feniletanoidi contro Candida spp. e loro effetto sinergico con amfotericina B.
DEL BIANCO, CAMILLA
2025/2026
Abstract
The current global healthcare landscape is increasingly threatened by the emergence of multidrug-resistant fungal strains. This phenomenon has prompted international health organizations to classify several fungal pathogens, including two species belonging to the genus Candida, among pathogens of critical priority. Current therapeutic strategies, which rely predominantly on azoles, polyenes, and echinocandins, are subject to significant limitations due to the emergence of resistance mechanisms and the toxicity associated with some treatments. An additional major challenge affecting healthcare systems is represented by skin wounds, particularly chronic wounds, which are associated with high morbidity and substantial economic costs, thereby contributing to delays in the clinical management of affected patients. The healing of these lesions is frequently impaired by the development of polymicrobial infections, in which Candida represents a clinically relevant pathogen. Within this context, phenylethanoid glycosides, owing to their antimicrobial and anti inflammatory properties, may represent potential multifunctional therapeutic agents, as they have the potential to target two critical aspects of wound management: infection control and the inflammatory processes involved in wound healing. The aim of the present thesis was to evaluate the antifungal activity of two plant-derived compounds, ABR1 and ABR2, containing the phenylethanoid glycosides verbascoside and plantamajoside, respectively, using C. albicans as the reference organism. Their antifungal activity was assessed both as single agents and in combination with amphotericin B. In addition, ABR2 was tested against 15 clinical isolates belonging to the genus Candida. A preliminary assessment of cytotoxicity was performed using 3T3 fibroblasts, and an in vitro skin wound model was established by means of a scratch assay. The results showed that ABR1 and ABR2 exhibited antifungal activity when administered as single agents at concentrations of 40,000 mg/L and 48,000 mg/L, respectively. In the presence of amphotericin B at 0.0625 mg/L, the effective concentrations decreased to 156 mg/L and 188 mg/L, respectively. The analysis of the clinical isolates revealed a variable response to ABR2. Finally, the experiments performed on fibroblasts and the scratch assay indicated that ABR1 and ABR2, at concentrations effective in combination with amphotericin B, were compatible with fibroblast viability when administered as single agents, whereas their combination with amphotericin B resulted in reduced cellular compatibility, likely due to limited selectivity.| File | Dimensione | Formato | |
|---|---|---|---|
|
DelBianco_Camilla.pdf
Accesso riservato
Dimensione
3.91 MB
Formato
Adobe PDF
|
3.91 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/118515